What is the clinical evidence from this study?

Study design: Review. Population: chronic kidney disease (CKD) associated with type 2 diabetes. Intervention: Finerenone vs. placebo. Primary outcome: serious kidney outcomes and major cardiovascular events.

What does this research mean for the field?

Finerenone reduces serious kidney outcomes by 23% and major cardiovascular events by 14% compared with placebo in patients with chronic kidney disease associated with type 2 diabetes. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The review aims to summarize the benefits of finerenone in patients with chronic kidney disease and type 2 diabetes.

July 1, 2026Cardiology in Review

Finerenone and Cardiorenal Outcomes: A Narrative Review

View Full Paper

Ask AI

Bookmark

Key result

Finerenone cuts serious kidney outcomes ~23% and lowers major CV events vs placebo in diabetic CKD.

Why the study?

Despite renin-angiotensin system inhibitors and SGLT2 inhibitor therapy, many patients with CKD associated with type 2 diabetes experience worsening kidney function and cardiovascular events.

Does finerenone reduce serious kidney outcomes and major cardiovascular events in patients with chronic kidney disease associated with type 2 diabetes?

Design

Narrative review

Authors

WFWerner Fernandes STSanzana Tasneem FLFaizaan Latif

Discussion

Member takes

Implication

Supports adding finerenone for residual cardiorenal risk in T2D-CKD; confirms benefits atop RASi/SGLT2i.

Key Points

The review aims to summarize the benefits of finerenone in patients with chronic kidney disease and type 2 diabetes.
Review of evidence from clinical trials and real-world studies published from 2014 to 2025.
Includes analyses from studies like FIDELIO-DKD and FIGARO-DKD.
Evaluates finerenone's effect on cardiorenal outcomes alongside standard therapies.
Finerenone treatment led to a 30% reduction in urine albumin-to-creatinine ratio within the first months.
Pooled analyses indicated a 23% reduction in serious kidney outcomes and a 14% reduction in major cardiovascular events compared to placebo.
Hyperkalemia occurred more frequently with finerenone, but discontinuation rates were low.

Structured PICO

Does finerenone reduce serious kidney outcomes and major cardiovascular events in patients with chronic kidney disease associated with type 2 diabetes?

Population

Patients with chronic kidney disease (CKD) associated with type 2 diabetes

Intervention

Finerenone (added to background angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy)

Comparator

Placebo

Outcome

Serious kidney outcomes and major cardiovascular eventscomposite

Finerenone provides significant cardiorenal risk reduction in patients with CKD and type 2 diabetes, reducing serious kidney outcomes and major cardiovascular events compared to placebo.

Limitations

Direct randomized endpoint comparisons with spironolactone or eplerenone remain lacking.
Direct randomized endpoint comparisons with spironolactone or eplerenone remain lacking

Cite This Study

Fernandes et al. (2026) conducted a review in chronic kidney disease (CKD) associated with type 2 diabetes. Finerenone vs. placebo was evaluated on serious kidney outcomes and major cardiovascular events. Finerenone reduced serious kidney outcomes by 23% and major cardiovascular events by 14% compared with placebo in patients with CKD associated with type 2 diabetes.

synapsesocial.com/papers/6a44af895cd2549c8bc44790 https://doi.org/10.1097/crd.0000000000001377

View Full Paper

Ask AI

Bookmark

Finerenone and Cardiorenal Outcomes: A Narrative Review

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Finerenone and Cardiorenal Outcomes: A Narrative Review

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider